Alzheimer’s Drug Discovery Foundation (FDT) and The Association for Frontotemporal Degeneration (AFTD): Accelerating Drug Discovery for Frontotemporal Dementias (FTD) - Letter of Intent

The ADDF/AFTD seek to accelerate and support drug discovery for FTD and related dementias (WILL NOT SUPPORT APPLICATIONS FOR BASIC RESEARCH). The program will provide grants one-year grants of up to $150,000 each, with the possibility of follow-on funding. Priority areas for this program include:

• Development of biomarkers to accelerate drug development and early diagnosis;

• Innovative pilot clinical trials;

• Target validation studies;

• Development and testing of novel high throughput screening assays;

• Medicinal chemistry on lead compounds;

• Identification and in vitro testing of potentially disease modifying lead compounds;

• ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds; and,

• Testing of lead compounds in a relevant animal model for preclinical proof of concept.

http://www.alzdiscovery.org